JP2014156484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014156484A5 JP2014156484A5 JP2014108085A JP2014108085A JP2014156484A5 JP 2014156484 A5 JP2014156484 A5 JP 2014156484A5 JP 2014108085 A JP2014108085 A JP 2014108085A JP 2014108085 A JP2014108085 A JP 2014108085A JP 2014156484 A5 JP2014156484 A5 JP 2014156484A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer cells
- receptor antagonist
- cancer
- human prolactin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 5
- 229940044551 receptor antagonist Drugs 0.000 claims 5
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 claims 2
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 102000003998 progesterone receptors Human genes 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15562409P | 2009-02-26 | 2009-02-26 | |
| US61/155,624 | 2009-02-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Division JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014156484A JP2014156484A (ja) | 2014-08-28 |
| JP2014156484A5 true JP2014156484A5 (enExample) | 2015-04-16 |
Family
ID=42133705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Expired - Fee Related JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
| JP2014108085A Pending JP2014156484A (ja) | 2009-02-26 | 2014-05-26 | がん幹細胞を可視化・排除するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552066A Expired - Fee Related JP5963443B2 (ja) | 2009-02-26 | 2010-02-16 | がん幹細胞を可視化・排除するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754035B2 (enExample) |
| EP (1) | EP2400979B1 (enExample) |
| JP (2) | JP5963443B2 (enExample) |
| KR (1) | KR101672401B1 (enExample) |
| CN (2) | CN102341118A (enExample) |
| AU (1) | AU2010218261B2 (enExample) |
| CA (1) | CA2753804C (enExample) |
| IL (2) | IL214545A (enExample) |
| WO (1) | WO2010099003A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648046B2 (en) * | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
| EP2576823A1 (en) * | 2010-06-04 | 2013-04-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence |
| DK2935331T3 (en) | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| US20170128527A1 (en) * | 2014-06-18 | 2017-05-11 | Prorec Bio Ab | Prolactin receptor antagonists for treatment of glioblastoma |
| CN107198779A (zh) * | 2016-11-29 | 2017-09-26 | 南京东纳生物科技有限公司 | 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用 |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| WO2020011998A1 (en) * | 2018-07-13 | 2020-01-16 | Hifibio Sas | Use of droplet single cell epigenome profiling for patient stratification |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1055932A (en) | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
| DE2616086C2 (de) | 1976-04-13 | 1986-04-03 | Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg | Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin |
| EP1079851B1 (en) | 1998-05-12 | 2007-07-04 | Greenville Hospital System | Use of anti-prolactin agents to treat cancer |
| WO2001045746A2 (en) * | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| CA2411244A1 (en) | 2000-05-09 | 2001-11-15 | Greenville Hospital System | Therapeutic pore-forming peptides |
| HUP0401268A2 (hu) * | 2001-07-31 | 2004-11-29 | Pfizer Products Inc. | Ösztrogén agonisták/antagonisták, ösztrogének és progesztinek kombinációját tartalmazó gyógyszerkészítmények, valamint eljárás ezek előállítására |
| WO2003082301A1 (en) * | 2002-03-29 | 2003-10-09 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| KR101045401B1 (ko) | 2002-09-11 | 2011-06-30 | 프레제니우스 카비 도이치란트 게엠베하 | 하이드록시알킬 전분 유도체 |
| MXPA05006945A (es) * | 2002-12-26 | 2005-12-14 | Mountain View Pharmaceuticals | Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor. |
| US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US20050238628A1 (en) * | 2004-04-08 | 2005-10-27 | Blau Carl A | Methods for treating cancer |
| US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| US8420665B2 (en) * | 2008-01-11 | 2013-04-16 | Northwestern University | Anti-cancer compounds |
-
2010
- 2010-02-16 EP EP20100705493 patent/EP2400979B1/en not_active Not-in-force
- 2010-02-16 WO PCT/US2010/024340 patent/WO2010099003A2/en not_active Ceased
- 2010-02-16 CN CN2010800089960A patent/CN102341118A/zh active Pending
- 2010-02-16 KR KR1020117022422A patent/KR101672401B1/ko not_active Expired - Fee Related
- 2010-02-16 AU AU2010218261A patent/AU2010218261B2/en not_active Ceased
- 2010-02-16 CN CN201610657107.2A patent/CN106177954A/zh active Pending
- 2010-02-16 US US12/706,702 patent/US8754035B2/en not_active Expired - Fee Related
- 2010-02-16 CA CA2753804A patent/CA2753804C/en not_active Expired - Fee Related
- 2010-02-16 JP JP2011552066A patent/JP5963443B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-09 IL IL214545A patent/IL214545A/en not_active IP Right Cessation
-
2014
- 2014-05-26 JP JP2014108085A patent/JP2014156484A/ja active Pending
-
2016
- 2016-06-15 IL IL246247A patent/IL246247A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014156484A5 (enExample) | ||
| Iqbal et al. | Plant-derived anticancer agents: A green anticancer approach | |
| Bhatt et al. | Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status | |
| Sagoo et al. | Primary intraocular lymphoma | |
| McCubrey et al. | Targeting breast cancer initiating cells: advances in breast cancer research and therapy | |
| Shi et al. | Alpha B-crystallin promotes the invasion and metastasis of colorectal cancer via epithelial-mesenchymal transition | |
| SG10201803533YA (en) | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof | |
| JP2018512443A5 (enExample) | ||
| Izar et al. | Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer | |
| NZ599031A (en) | A dosage form containing two or more active pharmaceutical ingredients in different physical forms | |
| CN109475535A (zh) | 癌症的联合治疗 | |
| JP2017031059A (ja) | がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤 | |
| Popadyuk et al. | Synthesis and biological activity of novel deoxycholic acid derivatives | |
| MX2018006527A (es) | Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer. | |
| JP2014523398A5 (enExample) | ||
| WO2017053555A8 (en) | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs | |
| JP2015522025A5 (enExample) | ||
| JP2015506352A5 (enExample) | ||
| MX2019012044A (es) | Vacuna para enfermedad intrauterina. | |
| WO2015026934A8 (en) | Bruton's tyrosine kinase as anti-cancer drug target | |
| CN203682011U (zh) | 一种兽药可溶性粉剂分装铲 | |
| Arora et al. | SPR965: an oral PI3K/mTOR C1/C2 inhibitor for the treatment of solid tumors | |
| Nakhjavani et al. | Studying the effect of methylparaben and propylparaben on growth curve of human breast adenocarcinoma cell line | |
| Jie | Opportunities of Inner Mongolia's economic development under the background of the “Silk Road Economic Belt” | |
| Finn et al. | P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2− Negative (HER2–) Advanced Breast Cancer. |